<DOC>
	<DOCNO>NCT00043264</DOCNO>
	<brief_summary>Multiple sclerosis ( MS ) inflammatory , demyelinate disease affect central nervous system ( CNS ) . The etiology MS unknown , although immune system appear play role . Many different infectious agent propose potential cause MS , include Epstein-Barr virus , human herpesvirus 6 , coronaviruses . Recently Dr. Sriram Vanderbilt University find evidence active Chlamydia pneumonia infection CNS MS patient . These finding replicate part laboratory . The purpose current study test whether antibiotic treatment aim eradicate Chlamydia infection reduce disease activity MS . The primary outcome measure reduction new enhance MS lesion brain MRI . Forty patient enter trial . To eligible , patient must evidence chlamydia infection spinal fluid enhance lesion pre-randomization MRI scan . Patients meet criterion randomize either placebo antibiotic therapy , follow 6 month treatment .</brief_summary>
	<brief_title>Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Patients unequivocal diagnosis multiple sclerosis evidence C. pneumoniae infection cerebral spinal fluid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2003</verification_date>
</DOC>